Search results for "Highlights"


 
Results 1 - 10 of about 440 for "Highlights".
Sort by: Relevance | Newest | Oldest

Real-time and intermittently scanned CGM associated with improved glycemic control in type 2 diabetes

A meta-analysis of 12 trials found that continuous glucose monitoring (CGM) resulted in an average difference in HbA1c of −0.31% versus self-monitoring, with a trend toward a larger effect with real-time monitoring.
https://diabetes.acponline.org/archives/2024/03/08/2.htm
8 Mar 2024

Position statement calls for prioritizing patients' experience in diabetes care

The Endocrine Society's recommendations are based on roundtable meetings with representatives from governmental and other organizations, patient advocacy groups, and professional societies, including ACP.
https://diabetes.acponline.org/archives/2024/03/08/3.htm
8 Mar 2024

Basal insulin does not contribute to emotional distress in type 2 diabetes, study finds

A randomized trial found no evidence that basal insulin affected emotional distress and indicated that insulin glargine and liraglutide were associated with a modest decrease in diabetes-related distress at one year.
https://diabetes.acponline.org/archives/2024/03/08/1.htm
8 Mar 2024

Certain beverages associated with CVD risk in type 2 diabetes patients

For each increase of one unit per day in consumption of sugar-sweetened beverages, artificially sweetened beverages, and natural juices, risk for cardiovascular disease (CVD) was 11%, 9%, and 16% higher, respectively, a study of U.K. data found. Coffee and tea were not associated with CVD.
https://diabetes.acponline.org/archives/2024/02/09/2.htm
9 Feb 2024

SGLT-2 inhibitors associated with lower risk of kidney stones vs. other new diabetes drugs

Possible mechanisms to explain the association include increased urinary citrate excretion, increased urinary bicarbonate excretion that raises urine pH, or anti-inflammatory effects.
https://diabetes.acponline.org/archives/2024/02/09/3.htm
9 Feb 2024

Liraglutide had best outcomes in trial of second-line therapies added to metformin

Patients randomized to liraglutide had a 60.3% risk of reaching a composite outcome of glycemic deterioration, weight gain, or hypoglycemia compared with 81.4% on glimepiride, 71.9% on glargine, and 69.6% on sitagliptin.
https://diabetes.acponline.org/archives/2024/02/09/1.htm
9 Feb 2024

AHA releases scientific statement on diabetic foot ulcers in cardiovascular patients

Qualitative and quantitative research is needed to resolve the reasons behind amputations for diabetic foot ulcers, the American Heart Association (AHA) said.
https://diabetes.acponline.org/archives/2024/01/12/3.htm
12 Jan 2024

Spotlight on the 2024 Standards of Care

The American Diabetes Association made its annual updates to the Standards of Care in Diabetes, addressing newer drug classes and growing evidence for bariatric surgery and heart failure screening, among many other changes.
https://diabetes.acponline.org/archives/2024/01/12/5.htm
12 Jan 2024

Most second-line treatments for type 2 diabetes modified within year of initiation

Among patients with type 2 diabetes put on a second-line drug, 38.6% discontinued the medication within one year of starting, 19.8% intensified the medications, and 5.2% of patients switched drug classes, according to data from over 82,000 U.S. patients.
https://diabetes.acponline.org/archives/2024/01/12/2.htm
12 Jan 2024

Physical activity may weaken association between cognitive decline and diabetes

Diabetes increased risk for cognitive impairment among inactive but not active adults in a cohort study in Brazil, and active adults with diabetes developed cognitive impairment 2.73 years later, on average, than the inactive diabetes patients.
https://diabetes.acponline.org/archives/2024/01/12/1.htm
12 Jan 2024

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next